Status:

TERMINATED

Efficacy and Safety of PLACENTEX ® i.m. in Patients With Scleroderma Diseases

Lead Sponsor:

Mastelli S.r.l

Collaborating Sponsors:

Sintesi Research Srl

Conditions:

Scleroderma Disease

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

This is a phase IV, single-arm, open-label clinical trial to evaluate the efficacy and safety of PLACENTEX ® Polydeoxyribonucleotide i.m. in patients with fibrotic and atrophic cutaneous lesions in sc...

Detailed Description

This is a phase IV, single-arm, open-label clinical trial to evaluate the efficacy and safety of PLACENTEX ® Polydeoxyribonucleotide 5.625 mg/3 ml for parenteral use i.m. in patients with fibrotic and...

Eligibility Criteria

Inclusion

  • Male or female age \> 18 years.
  • Patients diagnosed with localized scleroderma diseases during inactive stage with fibrotic and atrophic cutaneous lesions confirmed histologically.
  • Understanding the nature of the study and Signature of the written informed consent.
  • Negative pregnancy test at study entry for females of child bearing potential.
  • If the patient is a female of childbearing potential (less than 24 months since the last menstrual bleeding), she is using an acceptable and effective method of contraception during the study period.

Exclusion

  • Patients under treatment with steroid therapy and/or systemic immunosuppressive therapy within 1 month prior to screening.
  • Patients with ongoing infectious processes at the level of target lesions.
  • Women who are pregnant or breast feeding.
  • Know allergy or hypersensitivity to the active principle of the investigational drug or to one of its excipients.
  • Patients with a condition or concurrent severe and/or uncontrolled medical disease which could compromise his/her participation, compliance with and/or completion of study procedures.

Key Trial Info

Start Date :

November 8 2016

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 31 2019

Estimated Enrollment :

25 Patients enrolled

Trial Details

Trial ID

NCT03388255

Start Date

November 8 2016

End Date

October 31 2019

Last Update

September 16 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

IRCCS Ca' Granda Ospedale Maggiore Policlinico

Milan, Italy, 21122